A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy

被引:49
|
作者
Huang, Xiaoping [1 ]
Zhang, Ying [1 ]
Tang, Yaqiong [1 ]
Butler, Napoleon [1 ]
Kim, Jungeun [1 ]
Guessous, Fadila [1 ]
Schiff, David [2 ]
Mandell, James [3 ]
Abounader, Roger [1 ,2 ,4 ]
机构
[1] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA
[4] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA
来源
NEOPLASIA | 2013年 / 15卷 / 08期
基金
美国国家卫生研究院;
关键词
TUMOR-SUPPRESSOR; MUTANT P53; GAIN; MYC; EXPRESSION; MUTATIONS; TRANSCRIPTION; GENE;
D O I
10.1593/neo.13376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most frequently mutated tumor suppressors in human cancer including in glioblastoma. Here, we show that PTEN exerts unconventional oncogenic effects in glioblastoma through a novel PTEN/mutant p53/c-Myc/Bcl-XL molecular and functional axis. Using a wide array of molecular, genetic, and functional approaches, we demonstrate that PTEN enhances a transcriptional complex containing gain-of-function mutant p53, CBP, and NFY in human glioblastoma cells and tumor tissues. The mutant p53/CBP/NFY complex transcriptionally activates the oncogenes c-Myc and Bcl-XL, leading to increased cell proliferation, survival, invasion, and clonogenicity. Disruption of the mutant p53/c-Myc/Bcl-XL axis or mutant p53/CBP/NFY complex reverses the transcriptional and oncogenic effects of PTEN and unmasks its tumor-suppressive function. Consistent with these data, we find that PTEN expression is associated with worse patient survival than PTEN loss in tumors harboring mutant p53 and that a small molecule modulator of p53 exerts greater antitumor effects in PTEN-expressing cancer cells. Altogether, our study describes a new signaling pathway that mediates context-dependent oncogenic/tumor-suppressive role of PTEN. The data also indicate that the combined mutational status of PTEN and p53 influences cancer prognosis and anticancer therapies that target PTEN and p53.
引用
收藏
页码:952 / +
页数:17
相关论文
共 4 条
  • [1] Expression of P53/PTEN/c-Myc in peripheral blood leukocytes from patients with breast cancer and its clinical significance
    Huang, Guangcheng
    Ma, Qiang
    Zou, Jiang
    Sun, Ru
    Yao, Lihua
    Xu, Lei
    Wang, Dongsheng
    Guo, Xiaolan
    CANCER RESEARCH, 2017, 77
  • [2] A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer
    Grzes, Maria
    Jaiswar, Akanksha
    Grochowski, Marcin
    Wojtys, Weronika
    Kazmierczak, Wojciech
    Olesinski, Tomasz
    Lenarcik, Malgorzata
    Nowak-Niezgoda, Magdalena
    Kolos, Malgorzata
    Canarutto, Giulia
    Piazza, Silvano
    Wisniewski, Jacek R.
    Walerych, Dawid
    CELL DEATH & DISEASE, 2024, 15 (08):
  • [3] Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, C-myc, Bcl-XL, NF-κB, and p53
    Han, SS
    Chung, ST
    Robertson, DA
    Ranjan, D
    Bondada, S
    CLINICAL IMMUNOLOGY, 1999, 93 (02) : 152 - 161
  • [4] The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner
    Mao, Pingping
    Jardine, Mary
    Niemaszyk, Lynn
    Haghkerdar, Jessica
    Yang, Eric
    Yanco, Esty G.
    Desai, Damayanti
    Beyrouthy, Maroun
    Kerley-Hamilton, Joanna S.
    Freemantle, Sarah J.
    Spinella, Michael J.
    CANCER RESEARCH, 2012, 72